Start-Up Previews (02/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Building the Next-Generation of GPCR-Targeting Drugs," features profiles of Catena Pharmaceuticals, Dimerix Bioscience, Heptares Therapeutics and Trevena. Plus these Start-Ups Across Health Care: Carmat, Glycan Biosciences, Itero and MaRVis Technologies.

Catena Pharmaceuticals Inc. Also see "Catena Pharmaceuticals Inc." - Scrip, 1 February, 2009. is seeking anti-angiogenic GPCR-antagonist compounds, and has a license to one that targets a subset of GPCRs specific for lysophosphatidic acid (LPA). LPA is one of a family of fatty molecules called lysophospholipids that is generating increasing interest among scientists for their role in cell proliferation and inflammation. The company says its small molecules have shown early promise in a number of indications, from oncology to fibrosis and neuropathic pain. Catena will concentrate initially on developing antagonists to LPA receptors for the treatment of solid tumors.

[Dimerix Bioscience Pty. Ltd.] Also see "Dimerix Bioscience Pty. Ltd." - Scrip, 1 February, 2009. is using its proprietary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo